Stifel starts ‘under-appreciated growth story’ ClearPoint at Buy

Stifel analyst Mathew Blackman last night initiated coverage of ClearPoint Neuro with a Buy rating and $8 price target. ClearPoint is a “neuro-logistics” company facilitating the development and delivery of biologics and Interventional therapies administered directly into the brain, the analyst tells investors in a research note. The firm sees an “under-appreciated growth story” with the potential to deliver 20%-plus growth over the next several years with line-of-sight to profitability. The company has a “defensible moat” of neuro expertise, positioning it as the partner-of-choice for cutting-edge brain-centric interventions, says Stifel.